HomeELVN • NASDAQ
Follow
Enliven Therapeutics Inc
Previous close
$18.63
Day range
$18.30 - $18.69
Year range
$9.80 - $24.22
Market cap
854.46M USD
Avg Volume
155.11K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 22.73M | 123.64% |
Net income | -19.37M | -160.18% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -22.65M | -629.68% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 253.15M | 235.14% |
Total assets | 271.87M | 195.64% |
Total liabilities | 25.96M | 150.25% |
Total equity | 245.91M | — |
Shares outstanding | 41.35M | — |
Price to book | 3.13 | — |
Return on assets | -20.82% | — |
Return on capital | -22.36% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -19.37M | -160.18% |
Cash from operations | -12.48M | -53.25% |
Cash from investing | 38.69M | 38,402.97% |
Cash from financing | 90.00K | 103.79% |
Net change in cash | 26.29M | -32.07% |
Free cash flow | -6.45M | -74,666.67% |
About
Founded
2016
Headquarters
Website
Employees
46